000			03007nam a2200421 c4500
003			ES-MaUEC
006			a||||fo|||| 00| 0
007			cr nn nnnanaaa
710	2		_aSpringerLink (Online service) _9106996
999			_c115158 _d115158 _x1
001			115158
005			20230221040153.0
008			190626s2019 gw a o |||| 0|eng d
020			_a9783030178321
024	7		_a10.1007/978-3-030-17832-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280.L8 _b2019 EB
245	0	0	_aTargeted Therapies for Lung Cancer _cedited by Ravi Salgia.
250			_a1st ed. 2019.
264		1	_aCham _bSpringer International Publishing _c2019.
300			_a1 recurso en línea (IX, 238 páginas) _b19 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aCurrent Cancer Research _x2199-2584
490	0		_aMedicine (Springer-11650)
505	0		_a1. EGFR -- 2. ALK -- 3. ROS1 -- 4. B-RAF -- 5. MET -- 6. HER2 -- 7. NTRK -- 8. SCLC -- 9. Complexities of the Lung Tumor Microenvironment -- 10. KRAS -- 11. Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance.
520	3		_aThis book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient's genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
988			_aSpringer_Medicine_2019
650		7	_aPulmones _xCáncer _2embne _9168954
700	1		_aSalgia, Ravi _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030178314
776	0	8	_iPrinted edition: _z9783030178338
776	0	8	_iPrinted edition: _z9783030178345
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-17832-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b11/2019 _ea _zSI